Antiyinterleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization

Transplantation

Volumn 98, Issue 12, 2014, Pages 1262-1270

  Kim, Irene ^a   Wu, Gordon ^a   Chai, Ning Ning ^a   Klein, Andrew S ^a   Jordan, Stanley ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alloantibody recall response; AntiYIL 6R; B cell; ELISpot; Flow cytometry; Mice; Plasma cell; Tfh; Th17; Treg

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; HLA A2 ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ALLOANTIBODY; CXCR5 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, MOUSE; IMMUNOGLOBULIN G; INTERLEUKIN 17;

ALLOSENSITIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RECALL RESPONSE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FOLLICULAR T HELPER CELL; HELPER CELL; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; SPLEEN CELL; TH17 CELL; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-17; ISOANTIBODIES; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, CXCR5; RECEPTORS, INTERLEUKIN-6; SPLEEN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84925944179     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000437     Document Type: Article

References (31)

1. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
2. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194.
3. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611.
4. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215.
5. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998.
6. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
7. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922.
8. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990; 4: 2860.
9. Diehl SA, Schmidlin H, Nagasawa M, et al. IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol 2012; 90: 802.
10. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012; 52: 199.
11. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542.
12. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959.
13. Lissilaa R, Buatois V, Magistrelli G, et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol 2010; 185: 5512.
14. Fogal B, Yi T, Wang C, et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol 2011; 187: 6268.
15. Zhao X, Boenisch O, Yeung M, et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant 2012; 12: 90.
16. Heidt S, Segundo DS, Chadha R, et al. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010; 15: 456.
17. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graftversus-host responses after experimental allogeneic bone marrow transplantation.Clin Cancer Res 2011; 17: 77.
18. Wang H, Guan Q, Lan Z, et al. Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. Am J Physiol Renal Physiol 2012; 302: F276.
19. Wu G, Chai N, Kim I, et al. Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol 2013; 28: 138.
20. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332.
21. Van Kooten C, Van Oers MH, Aarden LA. Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes. Res Immunol 1990; 141: 341.
22. Maeda K, Mehta H, Drevets DA, et al. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 2010; 115: 4699.
23. Tomiyama-Hanayama M, Rakugi H, Kohara M, et al. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009; 297: F679.
24. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235.
25. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev 2013; 252: 146.
26. Eto D, Lao C, DiToro D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One 2011; 6: e17739.
27. Linterman MA, Beaton L, Yu D, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 2010; 207: 353.
28. Lüthje K, Kallies A, Shimohakamada Y, et al. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol 2012; 13: 491.
29. Komai T, Shoda H, Yamaguchi K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report. Mod Rheumatol 2013.
30. Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B-cells in vivo: Impaired somatic hypermutation in preswitch memory B-cells and modulation of mutational targeting in memory B-cells. Ann Rheum Dis 2011; 70: 1507.
31. Todo T, Wu G, Chai NN, et al. Anti-CD3ε induces splenic B220lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization. Int Immunol 2012; 24: 529.